Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325515 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL995191 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL6041219 | 0.93 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL6139041 | 0.87 | MEN1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL27597529 | 0.87 | MEN1 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL8507676 | 0.86 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2GABRB1 | |
| SCHEMBL9382586 | 0.84 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL642839 | 0.84 | SMN1; SMN2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL8709208 | 0.84 | ALOX15 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2PPARG | |
| SCHEMBL8709207 | 0.84 | ALOX15 (0.42) | MEN1KMT2AALDH1A1SMN1; SMN2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084176-B1 | BOC AND FMOC SOLID PHASE PEPTIDE SYNTHESIS | IPSEN MFG IRELAND LIMITED (IE) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017212390-A1 | PROCESS FOR LANREOTIDE ACETATE PREPARATION | EMCURE PHARMACEUTICALS LTD, (IN) | 2017-12-14 | — | — | WO | disclosed |
| US-9822146-B2 | Process for the manufacture of degarelix and its intermediates | FERRING B.V. (NL) | 2017-11-21 | — | — | US | disclosed |
| EP-2632935-B1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-09-21 | — | — | EP | disclosed |
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FERRING BV (NL) | 2016-05-26 | — | — | US | disclosed |
| US-20150284424-A1 | BOC AND FMOC SOLID PHASE PEPTIDE SYNTHESIS | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2015-10-08 | — | — | US | disclosed |
| US-9090654-B2 | Boc and Fmoc solid phase peptide synthesis | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2015-07-28 | — | — | US | disclosed |
| US-9090656-B2 | Process for the manufacture of Degarelix and its intermediates | FERRING B.V. (NL) | 2015-07-28 | — | — | US | disclosed |
| CN-104530190-A | Boc and Fmoc solid phase peptide synthesis | IPSEN MFG IRELAND LTD | 2015-04-22 | — | — | CN | disclosed |
| US-20130338337-A1 | BOC AND FMOC SOLID PHASE PEPTIDE SYNTHESIS | IPSEN MANUFACTURING IRELAND LIMITED (IE) | 2013-12-19 | — | — | US | disclosed |
| US-5147856-A | Administering cyclic peptide prior to, during, and after surgery | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1992-09-15 | — | — | US | disclosed |
| WO-1992013554-A1 | METHOD OF TREATING BENIGN AND MALIGNANT PROLIFERATIVE SKIN DISEASE | BIOMEASURE, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| EP-0389180-A1 | Peptides and their use in therapy | BIOMEASURE, INC. (US) | 1990-09-26 | — | — | EP | disclosed |
| US-4904642-A | Therapeutic somatostatin analogs | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0344297-A1 | TREATMENT OF CANCER WITH SOMATOSTATIN AND ANALOGS THEREOF | The Administrators of The Tulane Educational Fund (US) | 1989-12-06 | — | — | EP | disclosed |
| US-4853371-A | Therapeutic somatostatin analogs | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1989-08-01 | — | — | US | disclosed |
| EP-0298732-A2 | Therapeutic Somatostatin analogues | The Administrators of The Tulane Educational Fund (US) | 1989-01-11 | — | — | EP | disclosed |
| EP-0277419-A2 | Therapeutic somatostatin analogues | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 1988-08-10 | — | — | EP | disclosed |
| EP-0215171-A2 | Peptides | THE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND (US) | 1987-03-25 | — | — | EP | disclosed |
| EP-0166355-A2 | Substituted aminophenyl compounds and acylaminophenyl compounds and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145301-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | VIP, HABP2, DPP9 | MEN1 1744/4885KMT2A 3948/4885ALDH1A1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.